Z. Ning

发表

Quantitative structure-activity relationship study of histone deacetylase inhibitors.

Leming Shi, Chenzhong Liao, A. Xie, 2004, Current medicinal chemistry. Anti-cancer agents.

Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Yuankai Shi, X. Hao, Lin Yang, 2019, Journal of Hematology & Oncology.

Quantitative Structure-Activity Relationship Study of Bisphosphonates

Leming Shi, Chenzhong Liao, BioChem Press, 2003 .

Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.

M. J. Newman, Z. Ning, X. Lu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

P. Xing, Yuankai Shi, Z. Ning, 2012, Cancer Chemotherapy and Pharmacology.

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

M. J. Newman, Zhibin Li, Z. Ning, 2012, Cancer Chemotherapy and Pharmacology.

Study on Drug‐Drug Interactions Between Chiglitazar, a Novel PPAR Pan‐Agonist, and Metformin Hydrochloride in Healthy Subjects

L. Miao, Z. Ning, Hua Zhang, 2019, Clinical pharmacology in drug development.

An Integrated Biochemoinformatics System for Drug Discovery

Leming Shi, Weiming Hu, Zibin Li, 2006 .

CS2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency

Zhibin Li, Z. Ning, Xianping Lu, 2017, Cancer science.

Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes

Z. Ning, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS).

M. Zhang, Jun Liu, Xuefeng Yu, 2021, Science bulletin.

Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP).

Qifu Li, H. Tian, Wei Jia, 2021, Science Bulletin.

The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats

Quan Liu, Z. Shen, Su-juan Sun, 2006 .

Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study

Z. Ning, Xuening Li, Wei-li Chen, 2019, Clinical Drug Investigation.

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Z. Ning, Xianping Lu, X. Fu, 2022, Frontiers in Pharmacology.

Why ACE—overview of the development of the subtype-selective histone deacetylase inhibitor chidamide in hormone receptor positive advanced breast cancer

Z. Ning, 2020 .

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

Z. Ning, X. Ke, W. Li, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Results from amulticenter , open-label , pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

Z. Ning, X. Ke, W. Li, 2015 .

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.

Xinhao Wang, Zhibin Li, Z. Ning, 2016, Intractable & rare diseases research.

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma

Yuankai Shi, Z. Ning, Jun Zhu, 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Phthalide Lactones from Ligusticum chuanxiong inhibit lipopolysaccharide-induced TNF-alpha production and TNF-alpha-mediated NF-kappaB Activation.

Kun Zhang, Z. Ning, Xianping Lu, 2005, Planta medica.

Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.

Kun Zhang, Z. Ning, Xianping Lu, 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1.

Z. Shen, Jing Cheng, Z. Ning, 2006, Endocrinology.

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Ying Cheng, Yongmei Yin, M. Cristofanilli, 2019, The Lancet. Oncology.

Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment

Xin Fu, Kun Zhang, Zhibin Li, 2014 .

Naringenin and hesperetin, two flavonoids derived from Citrus aurantium up‐regulate transcription of adiponectin

Song Shan, Kun Zhang, Xian-Ping Lu, 2008, Phytotherapy research : PTR.

Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis.

Zhibin Li, Z. Ning, Xianping Lu, 2019, International immunopharmacology.

In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist

Z. Shen, Z. Li, B. Ko, 2012, PPAR research.

Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ

Wei Wang, Kun Zhang, Laiqiang Huang, 2017, PPAR research.

Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.

J. Wong, Tai-guang Jin, N. Zhang, 2012, Journal of medicinal chemistry.

Discovery and Development of HDAC Subtype Selective Inhibitor Chidamide: Potential Immunomodulatory Activity Against Cancers

Zhibin Li, Z. Ning, Xianping Lu, 2016 .

Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models

Zhibin Li, Z. Ning, Xianping Lu, 2019, Anti-cancer drugs.

Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer

Tao Wang, Zefei Jiang, C. Geng, 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice.

Chenzhong Liao, Jing Cheng, B. Ko, 2005, Biological & pharmaceutical bulletin.

Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.

Leming Shi, Chenzhong Liao, Jiaju Zhou, 2004, Bioorganic & medicinal chemistry letters.

Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.

Tao Wang, Zefei Jiang, C. Geng, 2017 .